MedTrace Logo

Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects

NCT00701363 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2019-01-29

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to assess the efficacy of an extended injection interval schedule of lanreotide Autogel 120 mg in acromegalic subjects who are biochemically controlled on long term treatment with octreotide LAR 10 or 20 mg

Conditions

Interventions

DRUG

Lanreotide Autogel 120 mg

120mg, injections every 6 weeks, then depending on IGF-1 results at Week 24

Sponsors & Collaborators

Principal Investigators

  • Ipsen Medical Director · Ipsen

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2013-03-31
Completion
2013-05-31

Countries

  • Brazil
  • Denmark
  • Finland
  • France
  • Greece
  • Latvia
  • Netherlands
  • Norway
  • Poland
  • Romania
  • Russia
  • Serbia
  • South Korea
  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00701363 on ClinicalTrials.gov